A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

The PI3K/mTOR pathway is frequently aberrated in cancer. LY3023414 is a potent and selective ATP-competitive inhibitor of class I PI3K isoforms, mTOR, and DNA-PK. Here we report the dose-escalation results of the first-in-human phase I study of LY3023414. A 3+3 dose escalation for once-daily and twi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research Jg. 24; H. 14; S. 3253
Hauptverfasser:	Bendell, Johanna C, Varghese, Anna M, Hyman, David M, Bauer, Todd M, Pant, Shubham, Callies, Sophie, Lin, Ji, Martinez, Ricardo, Wickremsinhe, Enaksha, Fink, Aaron, Wacheck, Volker, Moore, Kathleen N
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 15.07.2018
Schlagworte:	Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Biomarkers Combined Modality Therapy Female Humans Male Middle Aged Neoplasm Metastasis Neoplasm Staging Neoplasms - diagnosis Neoplasms - drug therapy Neoplasms - metabolism Phosphoinositide-3 Kinase Inhibitors Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - pharmacokinetics Protein Kinase Inhibitors - therapeutic use Pyridines - administration & dosage Pyridines - adverse effects Pyridines - pharmacokinetics Pyridines - therapeutic use Quinolones - administration & dosage Quinolones - adverse effects Quinolones - pharmacokinetics Quinolones - therapeutic use Retreatment TOR Serine-Threonine Kinases - antagonists & inhibitors Treatment Outcome
ISSN:	1078-0432, 1557-3265, 1557-3265
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!